The factor VIII (FVIII), von Willebrand factor (vWF) and fibrinogen are extremely important in blood coagulation, with different physiological functions. Due to its higher concentrations of FVIII, von Willebrand factor (vWF), fibrinogen and factor XIII, the transfusion of cryoprecipitate is a therapy mainly recommended in patients with von Willebrand Disease, Hemophilia A (FVIII deficiency), or patients undergoing hypo or dysfibrinogenemia. This blood component is a precipitate obtained after partial thawing (between 1 and 6 ° C) of fresh frozen plasma, and is also known as antihaemophilic factor. Studies have shown that the freezing and storage protocols of cryoprecipitate affect the product quality and the viability of these factors. In order to assess the viability of canine cryoprecipitate in different freezing and storage protocols two groups composed of 10 units of canine cryoprecipitate will be evaluated (n=20). After centrifugation of the bags, the fresh plasma of the group I will be frozen at - 80°C and at -20°C in group II. Twenty-four hours after freezing, they will be subjected to the standard procedure of cryoprecipitate extraction. The cryoprecipitate of both groups will be evaluated by the determination of PT, APTT, FVIII, vWF and fibrinogen concentrations after zero and six months of storage. The evaluation of the effects of the freezing temperature and time of storage of the cryoprecipitate will be performed by ANOVA at the 5% significance level.
News published in Agência FAPESP Newsletter about the scholarship: